

# EASL – AASLD JOINT MEETING

## Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis

**London, United Kingdom**  
**30 September, 1 October 2017**

**Organising Committee:**  
Philippe Mathurin, France  
Vijay Shah, United States  
Gyongyi Szabo, United States  
Mark Thursz, United Kingdom

### **Saturday 30 September 2017**

**07:30 – 08:50**                      **Registration**

**08:50 – 09:00**                      **Welcome and opening remarks**  
*Gyongyi Szabo and Philippe Mathurin*

#### **Session 1: Epidemiology and progression factors of ALD** **Chair: Nick Sheron, United Kingdom**

09:00 – 09:20                      Burden and epidemiology of alcohol-related liver diseases in Europe and North America  
*David Leon, United Kingdom*

09:20 – 09:40                      Put us out of business: Role of health policy in controlling alcohol consumption  
*Sir Ian Gilmore, United Kingdom*

09:40 – 10:00                      Genetics of ALD: What do we learn from the risk loci about the disease?  
*Jochen Hampe, Germany*

10:00 – 10:15                      Discussion

**10:15 – 10:35**                      **Coffee break and ePoster session 1**

#### **Session 2: Translational science in ALD** **Chair: Tim Morgan, United States**

10:35 – 10:55                      Alcohol metabolism and cellular consequences  
*Laura Nagy, United States*

10:55 – 11:15                      From microbiome to intestinal inflammation in ALD  
*Bernd Schnabl, United States*

11:15 – 11:50                      Discussion

11:50 – 13:15	<b>Lunch and ePoster session 2+3</b>
13:15 – 13:35	Inflammation as a driver of ALD <i>Gyongyi Szabo, United States</i>
13:35 – 13:55	Alcohol related fibrogenesis <i>Christian Trautwein, Germany</i>
13:55 – 14:15	Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD? <i>Anna Mae Diehl, United States</i>
14:15 – 14:35	Animal models of ALD and alcoholic hepatitis: I favour the NIAAA model for targeting the key therapeutic pathways <i>Bin Gao, United States</i>
14:35 – 14:55	I favour the intragastric fat/alcohol model or targeting the key therapeutic pathways <i>Hidekazu Tsukamoto, United States</i>
14:55 – 15:10	Discussion
15:10 – 15:30	<b>Coffee break and ePoster session 4</b>

**Session 3: Clinical challenges in the management of patients with ALD**  
**Chair: Carolin Lackner, Austria**

15:30 – 16:00	Alcohol use disorder: diagnosis and management <i>Giovanni Addolorato, Italy</i>
16:00 – 16:20	Assessing co-factors in ALD <i>Arun Sanyal, United States</i>
16:20 – 16:35	Liver histology and AH/ALD-what is its role? <i>Dina Tiniakos, United Kingdom</i>
16:35 – 16:55	Liquid biopsy and biomarkers as a diagnostic measure and surrogate end-points <i>Vijay Shah, United States</i>
16:55 – 17:15	Non-invasive assessment including imaging in early versus advanced ALD <i>Laurent Castera, France</i>
17:15 – 17:30	Discussion
17:30 – 18:00	<b>State-of-the-Art Lecture:</b> Molecular pathways in hepatocellular carcinoma <i>Michael Karin, United States</i>
18:00 – 19:00	<b>Welcome reception and ePoster session 5+6</b>
20:00	<b>Faculty dinner</b>

## Sunday 1 October 2017

### Session 4: Management and treatment of alcoholic hepatitis (AH)

Chair : John O'Grady, London, United Kingdom

- |               |   |
|---------------|---|
| 08:00 – 08:20 | Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival<br><i>Patrick Kamath, United States</i>                |
| 08:20 – 08:40 | SIRS and management of infection in AH<br><i>Ramon Bataller, United States</i>  |
| 08:40 – 8:55  | Early liver transplantation in AH – Pro and Con debate:<br>I do not favour broader use of early liver transplantation for AH<br><i>Michael Lucey, United States</i> |
| 8:55 - 9:10   | I favour broader use of early liver transplantation in AH<br><i>Philippe Mathurin, France</i>   |
| 09:10 – 09:30 | Post-transplant complications/what is specific for ALD<br><i>Patrizia Burra, Italy</i>  |
| 09:30 – 09:50 | Alcohol relapse after transplantation: does-it matter?<br><i>Georges-Philippe Pageaux, France</i>   |
| 09:50 – 10:05 | Discussion  |
| 10:05 – 10:25 | <b>Coffee break and ePoster session 7</b>   |

### Session 5: Clinical trial design and end-points: perspectives of agencies

Chair : Helmut Seitz, Germany

- |               |  |
|---------------|--|
| 10:25 – 10:45 | Cost and mortality attributed to ALD<br><i>Rehm Jürgen, Canada</i>   |
| 10:45 – 11:05 | Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH<br><i>Christopher Leptak, United States</i> |
| 11:05 – 11:25 | EMA process to validate end-points for drug approval: specific requirements for AH<br><i>EMA</i>   |
| 11:25 – 11:40 | Discussions  |
| 11:40 – 13:00 | <b>Lunch and ePoster Session 8</b>   |

**Session 6: Future development of drugs in alcoholic hepatitis: Perspectives of the investigators**

**Chair: Laurent Spahr, Switzerland**

- |               |   |
|---------------|---|
| 13:00 – 13:20 | Patient characteristics and end-points in clinical trials for early ALD<br><i>Helena Cortez Pinto, Portugal</i>                         |
| 13:20 – 13:40 | Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials<br><i>Mark Thursz, United Kingdom</i>           |
| 13:40 – 14:00 | Clinical trial design: What is the optimal plan of development from phase I to Phase III?<br><i>Alexandre Louvet, France</i>            |
| 14:00 – 14:20 | How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD<br><i>Alexander Krag, Denmark.</i>  |
| 14:20 – 14:40 | Lessons learned from NASH CRN and DILI network on clinical networks, sample and data collection<br><i>Naga Chalasani, United States</i> |
| 14:40 – 15:00 | Which therapeutic targets will be the most attractive in the future?<br><i>Craig McClain, United States</i>                             |
| 15:00 – 15:30 | <b>Break and poster session</b>   |

**Session 7: Future development of drugs in alcoholic hepatitis: Industry perspectives**

**Chair: Mack Mitchell, USA**

- |             |   |
|-------------|---|
| 15:30-16:45 | <i>3-4 pharma leaders to give a brief, 5-8 min overview of their plans/perspectives/challenges on clinical trials in ALD/AH<br/>Give each 15 min (presentation+ discussion)</i> |
| 16:45       | Discussions & Closing Remarks<br><i>Vijay Shah and Mark Thursz</i>  |